Human Growth Hormone

Phase 3Small molecule

AAscendis Pharma A/S

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Short Stature (ISS)Not yet recruiting

Idiopathic Short Stature (ISS)Phase 3

Not yet recruiting

Timeline

Expected Milestones

Q1 2029

Phase 3Not yet recruiting

Idiopathic Short Stature (ISS)

NCT07815626

Q4 2036

Phase 2Recruiting

Short Stature

NCT06382155

Clinical

Trials by Indication[1]

Growth3 trials

Growth Hormone Signaling in Vivo in Humans

Completed·UUniversity of Aarhus·N/A·NCT00512473·8 enrolled

Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF

Unknown status·CCenter for Human Reproduction·Phase 1/2·NCT02179255·30 enrolled

A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.

Completed·RRoyal Marsden NHS Foundation Trust·Phase 2/3·NCT00300664·150 enrolled

Growth Hormone Deficiency2 trials

Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency

Completed·SStanford University·Phase 3·NCT01007071·11 enrolled

A Multicenter, Phase 2, Randomized, Open Label, Active-controlled, Parallel-group Study Investigating the Safety, Tolerability, and Efficacy of Different Dose Levels of ACP-001 Administered Once Weekly Versus Standard Daily rhGH Replacement Therapy in Pre-pubertal Children With Growth Hormone Deficiency (GHD)

Completed·AAscendis Pharma A/S·Phase 2·NCT01947907·53 enrolled

Treatment1 trial

Treatment of GHD Associated With CHF

Unknown status·FFederico II University·Phase 3·NCT03775993·64 enrolled

Short stature1 trial

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

Recruiting· BioMarin Pharmaceutical logo

BioMarin Pharmaceutical·Phase 2·NCT06382155·100 enrolled

Tics1 trial

Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)

Completed·AAscendis Pharma A/S·Phase 1·NCT01010425·44 enrolled

2 more indications

Dexamethasone1 trial

Dexamethasone/Pancreatic Clamp P&F

Withdrawn·—·Phase 1·NCT06126354

Idiopathic Short Stature (ISS)1 trial

A Multicenter, Randomized, Open-Label, Active-Controlled, Non-Inferiority Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature (ISS)

Not yet recruiting·ZZhongshan Sansure Hygene Biomedicine Co., Ltd.·Phase 3·NCT07815626·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Human Growth Hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Human Growth Hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Human Growth Hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ascendis Pharma A/S company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAscendis Pharma A/S